Provided by Tiger Trade Technology Pte. Ltd.

Intellia Therapeutics

13.24
-0.0200-0.15%
Post-market: 13.310.0700+0.53%16:12 EDT
Volume:5.70M
Turnover:77.42M
Market Cap:1.56B
PE:-3.48
High:14.02
Open:13.02
Low:12.82
Close:13.26
52wk High:28.25
52wk Low:5.90
Shares:118.13M
Float Shares:112.00M
Volume Ratio:1.62
T/O Rate:5.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8100
EPS(LYR):-3.8100
ROE:-53.48%
ROA:-27.11%
PB:2.33
PE(LYR):-3.48

Loading ...

Intellia Therapeutics price target raised to $25 from $15 at H.C. Wainwright

TIPRANKS
·
Jan 28

Intellia Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $25 From $15

THOMSON REUTERS
·
Jan 28

Intellia Therapeutics Stock (NTLA) Pops as FDA Lifts Saftey Freeze on Nerve Disease Trial

TIPRANKS
·
Jan 27

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Opus Genetics (IRD) and Argenx Se (ARGX)

TIPRANKS
·
Jan 27

BUZZ-U.S. STOCKS ON THE MOVE-RTX, Kimberly-Clark, HCA Healthcare

Reuters
·
Jan 27

Intellia Therapeutics Shares up 23.7% Premarket After US FDA Lifts Clinical Hold on One of Co's Gene Therapy Trials

THOMSON REUTERS
·
Jan 27

Intellia Therapeutics Says FDA Lifts Hold on Phase 3 Trial of Nexiguran Ziclumeran; Shares Rise Pre-Bell

MT Newswires Live
·
Jan 27

US FDA lifts clinical hold on Intellia’s nerve disease trail

Reuters
·
Jan 27

Intellia Therapeutics Inc: Plan to Resume Magnitude-2 Patient Enrollment and Dosing

THOMSON REUTERS
·
Jan 27

Intellia Therapeutics Announces FDA Lift of Clinical Hold on Magnitude-2 Phase 3 Clinical Trial in Attrv-Pn

THOMSON REUTERS
·
Jan 27

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN

GlobeNewswire
·
Jan 27

A Look At Intellia Therapeutics (NTLA) Valuation After Safety Concerns And HAE Market Uncertainty

Simply Wall St.
·
Jan 24

Analysts Conflicted on These Healthcare Names: Clover Health Investments (CLOV) and Intellia Therapeutics (NTLA)

TIPRANKS
·
Jan 20

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Intellia Therapeutics (NTLA) and DocGo (DCGO)

TIPRANKS
·
Jan 15

Intellia Therapeutics (NTLA) Is Up 20.7% After FDA Halts MAGNITUDE ATTR-CM Trial Over Safety Event - Has The Bull Case Changed?

Simply Wall St.
·
Jan 15

Cathie Wood’s ARK Investment buys 40K shares of Intellia Therapeutics today

TIPRANKS
·
Jan 14

Is Intellia Therapeutics (NTLA) Pricing Reflect Recent Share Rebound Or Long Term Challenges

Simply Wall St.
·
Jan 12

Analysts Are Bullish on Top Healthcare Stocks: Intellia Therapeutics (NTLA), Roche Holding AG (RHHVF)

TIPRANKS
·
Jan 12

Synopsys, Reddit, Intellia, Symbotic, Seagate Insider Shock

TIPRANKS
·
Jan 10

Intellia Therapeutics VP and Chief Accounting Officer Michael P. Dube Reports Disposal of Common Shares

Reuters
·
Jan 08